New, Innovative CNS Drug Sought At End of Phase III Trial Level
Leiras Takeda Pharmaceuticals Finland flag Finland
Abstract ID:
New innovative drug to be used in some CNS-areas, primarily to support a product indicated for schizophrenia
Send an Inquiry
RE:
Participants
You

New innovative drug to be used in some CNS-areas, primarily to support a product indicated for schizophrenia.

Type of Business Relationship Sought

The clinical trials should have been mainly performed and there shouldn´t be a need for Takeda to make co-funding or co-development for the project.

FEATURED
Last Updated Sep 2014
Technology Type
Phase of Development CLINICAL TRIALS
CORPORATION

Opportunity Contact